Aegerion Pharmaceuticals, Inc.
Aegerion Pharmaceuticals Observes World Lipodystrophy Day
CAMBRIDGE, Mass., 2016-03-31 09:00 CEST (GLOBE NEWSWIRE) --
Aegerion Pharmaceuticals, Inc.(NASDAQ:AEGR), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating rare diseases, announced today its observance of World Lipodystrophy Day.
Chief Executive Officer Mary Szela said, "We support the Association of Families Affected by Lipodystrophies in Spain, Europe & Latin America(AELIP), Lipodystrophy United (LU), and others in the lipodystrophy community in their objective to increase awareness and diagnosis of this serious and often undiagnosed rare disease. Education is an important step towards making an impact for people affected by lipodystrophy.”
Lipodystrophy is a group of rare diseases characterized by the lack of fat tissue. In some patients, it is genetic, and in others it may be acquired. It can be characterized by a widespread lack of fat tissue under the skin (generalized lipodystrophy) or limited lack of fat tissue (partial lipodystrophy). This loss of fat tissue might cause a deficit in the hormone leptin leading to multiple medical complications such as severe metabolic complications.
“Lipodystrophies are rare diseases, meaning they can be difficult to diagnose correctly and therefore treat properly and efficiently,” said David Araújo-Vilar, MD, Professor of Medicine, Division of Endocrinology and Nutrition, University Clinical Hospital of Santiago de Compostela (Spain). “A common feature of most lipodystrophies is the predisposition to diabetes mellitus, dyslipidemia and cardiovascular diseases. Through increased awareness and education, physicians can more accurately diagnose and effectively treat these serious diseases.”
“Our objectives for World Lipodystrophy Day include raising awareness of the public health problem posed by lipodystrophy, implementing actions that impact the challenges faced by patients with lipodystrophy and their families, and joining together with the community to pool resources and improve care for those affected by this rare disease,” said Naca Pérez de Tudela, president of AELIP.
About Aegerion Pharmaceuticals
Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating, rare diseases. For more information about the company, please visitwww.aegerion.com.
Aegerion Pharmaceuticals, Inc.
Associate Director, Investor & Public Relations
Information om Globenewswire
Følg pressemeddelelser fra Globenewswire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Globenewswire
Meizu Technology ltd17.10.2018 15:15 | pressemeddelelse
Meizu officially launches its Overseas smartphone
Lithium Werks16.10.2018 14:39 | pressemeddelelse
€1.6bn investment project kickstarts Lithium Werks’ battery gigafactories vision
PureCircle16.10.2018 14:01 | pressemeddelelse
Global Beverage and Food Launches With Stevia Are Up Sharply In 2018
Talend16.10.2018 10:16 | pressemeddelelse
Talend Fall ’18 Enables Enterprises to Deliver Insight-Ready Data at Scale
Worksoft, Inc.16.10.2018 08:01 | pressemeddelelse
SAP® IT to Present on Agile Testing at SAP® TechEd® Barcelona Conference
LeddarTech inc.16.10.2018 07:01 | pressemeddelelse
LeddarTech Expands its Engineering Expertise and Accelerates its Design Roadmap to Meet Market Demand
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum